Abstract: Objective To analyze the effects of sacubitril valsartan sodium on the efficacy and overall function in the elderly patients with chronic heart failure (CHF). Methods A retrospective analysis was conducted in 80 patients with CHF from August 2020 to July 2023. These patients were divided into two groups according to the treatment methods, with 40 patients in each group. The control group was treated with enalapril, whereas the observation group was treated with sacubitril valsartan sodium. Before and after treatment, the scores of comprehensive geriatric assessment (CGA), the levels of renal function indicators, B-type natriuretic peptide (BNP) and echocardiography parameters were detected and compared between the two groups, and rehospitalization rate due to heart failure and the incidence rate of adverse reactions during treatment were recorded and compared between the two groups. Results Before treatment, there were no significant differences between the two groups in the scores of CGA, and the levels of renal function indicators, BNP and echocardiography parameters (P>0.05). After treatment, the scores of Activity of Daily Living scale and Hamilton Anxiety Scale and the levels of renal function indicators in the observation group were better than those in the control group. The levels of BNP, left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were significantly lower than those in the control group (P<0.05), while the levels of left ventricular ejection fraction (LVEF) and left ventricular fraction shortening (LVFS) were significantly higher than those in the control group (P<0.05). The rate of heart failure rehospitalization and the incidence rate of adverse reactions were significantly lower in the observation group than those in the control group (P<0.05). There were no differences in the scores of Mini-Mental State Examination, Hamilton Depression Scale and Nutrition Risk Screening 2002 between the two groups (P>0.05). Conclusions During the treatment period, sacubitril valsartan sodium can safely improve cardiac and renal function and daily living ability, reduce anxiety and the rehospitalization rate in the elderly patients with CHF.

Key words: sacubitril valsartan sodium, chronic heart failure, comprehensive geriatric assessment, B-type natriuretic peptide, renal function